As biopharma grows more complex, companies need more than manufacturing capacity. They need a partner that offers scientific expertise, operational flexibility, and a truly collaborative approach.
Key Takeaways:
At AGC Biologics, we're always looking for better ways to serve our partners. Our customers deserve more than square footage and bioreactors. They deserve a partner who brings scientific depth, operational flexibility, and a way of working that feels like an extension of their own team.
The developer-CDMO relationship has changed for the better. What used to be a simple capacity arrangement has grown into something much deeper: working together to determine the most efficient way to reach the market without compromising on quality. The best partnerships today are the ones where a CDMO becomes so aligned with a client’s technical operations that the two are hard to tell apart. When asked about what the CDMO of the future will look like, our CEO, Alberto Santagostino, put it well: " The best CDMO of the future is actually quite boring and uneventful, and I mean that in a positive way. It is about reliability. Nothing dramatic, nothing unexpected. It should just work.”
A CDMO should bring true technical expertise to every partnership, expertise deep enough to elevate a program in ways that are hard to build alone. It should also be straightforward and easy to work with. This combination makes economic sense. By building scale and learning across many products and companies, a CDMO creates efficiencies and builds a vast expertise that benefits everyone. Developing deep CMC expertise across biologics, ADCs, cell and gene therapy, and mRNA takes years of investment. Partnering with a CDMO lets your team tap into that expertise without building it in-house. You get access to capability without the capital risk, flexibility as your needs shift, and more room to focus your own resources where they matter most.
Our expertise runs deep because it was built by bringing together some of the industry's most respected specialized CDMOs, each with its own legacy of scientific firsts. Biomeva in Germany, now our Heidelberg site, was long regarded as one of the best microbial CDMOs in the world and was built in a German academic biotech hub. Our Milan site, formerly MolMed, has supported 18 commercial cell and gene product approvals and counting, and was the site of the first successful lentiviral therapy treatment in the late 1990s. CMC Biologics, now our Seattle and Copenhagen sites, pioneered single-use mammalian manufacturing technology in the early 2000s. Together, we are not a single organization competing on scale alone, but a string of pearls: niche leaders whose combined capabilities help our customers’ products reach patients with the quality and safety they deserve.
Pharmaceutical production is shifting away from a purely global model toward something more regional, and we're built for it. More than ever, our customers are asking for dual-region supply strategies, a real shift from the old model of concentrating production in a single location. Today, we offer microbial manufacturing in Seattle, Copenhagen, Heidelberg, and Chiba. Our mammalian capabilities span Seattle, Copenhagen, and Yokohama. For cell and gene therapy, we operate in Milan and Yokohama. This global but regionally distributed footprint means we're already positioned to support the resilient supply chains our partners need across North America, Western Europe, and Asia.
We back up our technical expertise and capabilities, as well as our regional distribution, with a track record we're proud of. We've passed more than 90 regulatory inspections across agencies including the FDA, EMA, and PMDA, making us a trusted, reliable partner from early development through commercial manufacturing. Our Seattle site recently earned GMP certification from Brazil's ANVISA, opening the door to South America’s largest pharmaceutical market. This spring, that same commitment to quality earned us the 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance, recognizing consistent, high-quality delivery across three continents. Our most active mammalian sites in Seattle and Copenhagen host 12+ global certifications each from regulatory bodies worldwide. This is a shining example of what a regulatory track record can offer as a CDMO – support in getting your final drug product to as many patients across the globe as possible.
So, what does friendly actually mean? It’s how we show up for our partners every day, not just what we build for them. Expertise gets a customer to the table. How we work together after that determines whether the partnership thrives. Being friendly doesn’t mean being a pushover. It means treating every relationship as reciprocal. As Alberto explains, "Being friendly does not mean being a servant. It means being fair, available, and collaborative. Of course, we need to make a profit, but we do not believe in squeezing customers simply because the market allows it. It is about finding an equitable balance in the relationship rather than extracting maximum short-term value."
That’s why we call ourselves a friendly CDMO expert instead of simply an expert CDMO. We understand that a fair, transparent, collaborative way of working is what grows partnerships, and it’s what our partners tell us they value most.
We're excited about where the industry is headed. As drug development grows more complex, successful partnerships will depend on more than capacity. Companies will look for partners with deep expertise, global reach, proven quality systems, and a genuinely collaborative way of working. That's what we mean when we say the future belongs to friendly CDMO experts, and it's the standard we hold ourselves to every day.
_____________________________
Ready to see what a friendly CDMO expert can do for your program? Contact us today for a free consultation on your project.